

Active studies

| Title | Phase | Tumortype | Line of Therapy | Study Information | Register |
|--|-------|----------------------------------|----------------------|--|-------------|
| First-line immunotherapy using Wilms' tumor protein 1 (WT1)-targeted dendritic cell vaccinations for malignant pleural mesothelioma (MESODEC) | I/II | MPM | 1L | <ul style="list-style-type: none"> • Epitheloid mesothelioma • Q3W: Pemetrexed + Cisplatinum + DC vaccination • Ongoing DC vaccination Q4W | NCT02649829 |
| A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-671) | III | NSCLC Stage II, IIIA or IIIB | Neoadjuvant/Adjuvant | <ul style="list-style-type: none"> • Neoadjuvant Q3W: Pembrolizumab/Placebo + Gemcitabine/Pemetrexed + Cisplatinum • Adjuvant Q3W: Pembrolizumab/Placebo | NCT03425643 |
| ALK, ROS1 and MET testing in cell-free RNA and DNA for improved precision oncology guided management of non-small cell lung cancer patients (LONG 18-05) | NA | NSCLC ROS, ALK and MET mutations | NA | The overall goal of the study is to assess the analytical performance to identify relevant mutations in ALK, ROS1 and MET in plasma from NSCLC patient. Doing so, we want to provide a rationale for a cost-effective testing procedure for future Belgian NSCLC patients for sensitive and straightforward mutation testing in easily accessible blood samples. | / |

| | | | | | |
|--|------------|---|-----------|--|--------------------|
| <p>A Phase III, Randomized, Double-blind, Placebo-controlled Study of Atezolizumab plus Carboplatin and Etoposide with or without Tiragolumab (Anti-TIGIT antibody) in Patients with Untreated Extensive-stage Small Cell Lung Cancer (SKYSCRAPER-02)</p> | <p>III</p> | <p>extensive-stage SCLC</p> | <p>1L</p> | <ul style="list-style-type: none"> • Induction 4x Q3W: Tiragolumab/Placebo + Atezolizumab + Carboplatin-Etoposide • Maintenance Q3W: Tiragolumab/Placebo + Atezolizumab | <p>NCT04256421</p> |
| <p>A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing LOXO-292 to Platinum-Based and Pemetrexed Therapy with or without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431)</p> | <p>III</p> | <p>NSCLC RET +</p> | <p>1L</p> | <ul style="list-style-type: none"> • Arm A BID: LOXO-292 (Selpercatinib) • Arm B Q3W: pemetrexed + carbo- or cisplatin +/- pembrolizumab → possibility to crossover to Arm A after progression | <p>NCT04194944</p> |
| <p>A Multicenter, Double Blind, Randomized, Controlled Study of M7824 with Concurrent Chemoradiation Followed by M7824 versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants with Unresectable Stage III Non-small Cell Lung Cancer</p> | <p>II</p> | <p>NSCLC Unresectable Stage III</p> | <p>1L</p> | <ul style="list-style-type: none"> • Arm 1: cCRT plus M7824 followed by M7824 • Arm 2: cCRT plus placebo followed by durvalumab | <p>NCT03840902</p> |

| | | | | | |
|---|-------------|--|------------|--|--------------------|
| <p>A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C</p> | <p>III</p> | <p>NSCLC Stage IV With Mutated KRAS p.G12C</p> | <p>≥2L</p> | <ul style="list-style-type: none"> • Arm 1: AMG 510 • Arm 2: docetaxel | <p>NCT04303780</p> |
| <p>An open-label, dose-escalation, phase I/II study to assess the safety, the tolerability, the immunogenicity and the preliminary clinical activity of the therapeutic cancer vaccine, PDC*lung01, associated or not with anti-PD-1 treatment in patients with non-small-cell lung cancer (NSCLC)</p> | <p>I/II</p> | <p>NSCLC</p> | <p>1L</p> | <ul style="list-style-type: none"> • SoC (+/- anti-PD-1) + PDC*lung01 | <p>NCT03970746</p> |
| <p>A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Tiragolumab in Combination With Atezolizumab plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Patients With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer (SKYSCRAPER-06)</p> | <p>II</p> | <p>NSCLC Stage IIIB-IV non-squamous</p> | <p>1L</p> | <ul style="list-style-type: none"> • Arm A: <ul style="list-style-type: none"> ○ Induction 4x Q3W: Tiragolumab + Atezolizumab + Pemetrexed + Carboplatin/Cisplatin ○ Maintenance: Q3W: Tiragolumab + Atezolizumab + Pemetrexed • Arm B: <ul style="list-style-type: none"> ○ Induction 4x Q3W: Placebo + Pembrolizumab + Pemetrexed + Carboplatin/Cisplatin ○ Maintenance: Q3W: Placebo + Pembrolizumab + Pemetrexed | <p>NCT04619797</p> |

| | | | | | |
|---|----|-------------------|----------|--|-------------|
| A Phase 2, Multicenter, Randomized Study to Compare the Efficacy and Safety of MK-7684A or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic Non-small Cell Lung Cancer With Progressive Disease After Treatment With a Platinum Doublet Chemotherapy and Immunotherapy | II | NSCLC Stage IV | 2L or 3L | <ul style="list-style-type: none">• Arm 1: MK-7684A + docetaxel• Arm 2: MK-7684A• Arm 3: Normal saline placebo + docetaxel | NCT04725188 |
|---|----|-------------------|----------|--|-------------|